LPCN - Lipocine Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8000
-0.0600 (-3.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.8600
Open1.8600
Bid1.7900 x 1000
Ask1.8600 x 800
Day's Range1.6400 - 1.8807
52 Week Range1.0400 - 2.6400
Volume117,520
Avg. Volume116,209
Market Cap44.235M
Beta (3Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.5600
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
Trade prices are not sourced from all markets
  • What Percentage Of Lipocine Inc. (NASDAQ:LPCN) Shares Do Insiders Own?
    Simply Wall St.5 days ago

    What Percentage Of Lipocine Inc. (NASDAQ:LPCN) Shares Do Insiders Own?

    A look at the shareholders of Lipocine Inc. (NASDAQ:LPCN) can tell us which group is most powerful. Institutions often...

  • Benzinga18 days ago

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

  • PR Newswire21 days ago

    Lipocine Set To Join Russell Microcap® Index

    SALT LAKE CITY, Utah, June 25, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2019 Russell indexes annual reconstitution. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "Joining the Russell Microcap Index is expected to contribute to increased investor awareness and broaden our investor base," said Dr. Mahesh Patel, President, Chief Executive Officer and Chairman of the Board of Lipocine.

  • Is Lipocine Inc.'s (NASDAQ:LPCN) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.last month

    Is Lipocine Inc.'s (NASDAQ:LPCN) Balance Sheet Strong Enough To Weather A Storm?

    While small-cap stocks, such as Lipocine Inc. (NASDAQ:LPCN) with its market cap of US$32m, are popular for their...

  • Zacks Small Cap Research2 months ago

    LPCN: Now We Have PDUFA Date; Target To $7

    By  John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT HERE First Quarter 2019 Operational and Financial Results On May 8, 2019 Lipocine (NASDAQ:LPCN) filed its 1Q:19 10-Q and posted ...

  • PR Newswire2 months ago

    Lipocine Announces TLANDO™ NDA PDUFA Action Date of November 9, 2019

    SALT LAKE CITY , May 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and ...

  • Associated Press2 months ago

    Lipocine: 1Q Earnings Snapshot

    The Salt Lake City-based company said it had a loss of 14 cents per share. The company's shares closed at $1.86. A year ago, they were trading at $1.57. _____ This story was generated by Automated Insights ...

  • PR Newswire2 months ago

    Lipocine Announces First Quarter 2019 Financial and Operational Results

    SALT LAKE CITY , May 8, 2019 /PRNewswire/ --   Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2019 , and provided a ...

  • Did You Manage To Avoid Lipocine's (NASDAQ:LPCN) Devastating 81% Share Price Drop?
    Simply Wall St.3 months ago

    Did You Manage To Avoid Lipocine's (NASDAQ:LPCN) Devastating 81% Share Price Drop?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Lipocine Inc. (NASDAQ:LPCN) share price...

  • Zacks Small Cap Research3 months ago

    LPCN: Turning the Tables

    During the approval of these competitors, Lipocine Inc. (LPCN) has been completing its blood pressure and ex vivo conversion studies in support of a 2Q:19 resubmission of its new drug application (NDA) so it can obtain approval and launch its own oral formulation of TRT. Clarus and Lipocine have been competing for the same market and also battling it out in the courts over patent conflicts. After the recent grant of Lipocine’s Priority Motion by the Patent Trial and Appeal Board (PTAB) and the adverse judgment against Clarus regarding the interference case, we see a low likelihood of a successful appeal by Clarus.

  • PR Newswire3 months ago

    Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy

    SALT LAKE CITY , April 3, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed ...

  • Zacks Small Cap Research4 months ago

    LPCN: ABPM Study Topline Data

    Lipocine (LPCN) distributed a press release yesterday announcing the completion of the Ambulatory Blood Pressure Monitoring (ABPM) clinical study and providing topline results. Blood pressure measurements were taken at baseline and at end of study with 118 subjects providing evaluable ABPM data. Results of the ABPM demonstrated a mean change of systolic blood pressure (SBP) of +3.82 mm Hg and diastolic blood pressure (DBP) of +1.20 mm Hg over the course of the study.

  • PR Newswire4 months ago

    Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy

    SALT LAKE CITY , March 27, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced findings from the ...

  • PR Newswire4 months ago

    Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers

    SALT LAKE CITY , March 26, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today acceptance of their abstract for late-breaker presentation on LPCN 1144 ...

  • PR Newswire4 months ago

    Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference

    SALT LAKE CITY , March 21, 2019 /PRNewswire/ --  Lipocine Inc.  (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and CEO, will provide a corporate ...

  • Zacks Small Cap Research4 months ago

    LPCN: NASH Topline

    By John Vandermosten, CFA NASDAQ:LPCN READ THE LATEST LPCN RESEARCH REPORT Lipocine (NASDAQ:LPCN) announced topline results from its non-alcoholic steatohepatitis (NASH) liver fat study demonstrating relative ...

  • PR Newswire4 months ago

    Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019

    SALT LAKE CITY , March 14, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part ...

  • Benzinga4 months ago

    Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate

    Lipocine Inc (NASDAQ: LPCN ) is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate. What Happened Lipocine ...

  • PR Newswire4 months ago

    Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population

    SALT LAKE CITY , March 12, 2019 /PRNewswire/ --  Lipocine Inc.  (NASDAQ: LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders, today announced top-line results from the ...

  • PR Newswire4 months ago

    Lipocine Announces Financial and Operational Results for the Year Ended December 31, 2018

    SALT LAKE CITY , March 6, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the year ended December 31, 2018 . Fourth Quarter ...

  • Does Lipocine Inc.’s (NASDAQ:LPCN) CEO Pay Reflect Performance?
    Simply Wall St.5 months ago

    Does Lipocine Inc.’s (NASDAQ:LPCN) CEO Pay Reflect Performance?

    Mahesh Patel became the CEO of Lipocine Inc. (NASDAQ:LPCN) in 1997. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll considerRead More...

  • PR Newswire5 months ago

    Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects

    SALT LAKE CITY , Feb. 14, 2019 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") indicated that ...

  • Zacks Small Cap Research6 months ago

    LPCN: Soldiering on and Winning Some Battles

    Lipocine (LPCN) published two press releases in the last two weeks signaling the advancement of LPCN 1144 towards a Phase II trial in non-alcoholic steatohepatitis (NASH) with biopsy confirmed NASH subjects. In the weeks prior, the company released other positive news regarding the grant of priority motion against Clarus and results from the phlebotomy study required to resubmit TLANDO.

  • ACCESSWIRE6 months ago

    4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Lipocine Inc., (LPCN), Microbot Medical Inc., (MBOT), and Capricor Therapeutics Inc., (CAPR) represent four healthcare companies determined to invest in the betterment of healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with up and coming technologies for the healthcare industry to create optimal care solutions for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced that the Company is moving forward with a binding Letter of Intent to a acquire two Metro Vancouver-based pharmacies.

  • PR Newswire6 months ago

    Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects

    SALT LAKE CITY , Jan. 24, 2019 /PRNewswire/ --  Lipocine Inc.  (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application ("IND") ...